PolyActiva and RareSight collaborate to create innovative therapies for rare pediatric retinal diseases, aiming to transform ...
In this inaugural episode of the Ophthalmology Times ® “Beyond The Walls” podcast, host Deborah Ristvedt, DO, of Vance ...
Dr. Andreas Wallnöfer joins Optigo Biotherapeutics' Board, bringing expertise from Jeito Capital, BioMedPartners, and Roche.
4D Molecular Therapeutics (4DMT) released positive interim 1.5- to 3.5-year data from the phase 1/2 PRISM clinical trial ...
Avisi Technologies has released positive 12-month clinical data on the VisiPlate Aqueous Shunt from the VITA Trial. The VITA ...
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your ...
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your ...
Topline results that were recently released from Sydnexis’s phase 3 Study of Atropine for the Reduction of Myopia Progression ...
The SOL-R registrational trial (NCT06495918) of OTX-TKI (AXPAXLI) by Ocular Therapeutix has reached its randomization target of 555 patients.
AAVantgarde Bio has announced the successful closing of a $141 million (€122 million) Series B financing round that was co-led by a new lead, Schroders Capital, as well as existing investors Atlas ...
Viridian seeks Priority Review for veligrotug, aiming for a potential mid-2026 commercial launch if approved. Global phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback